Publications
-
- Conference presentation
- [AACR 2026] DA-4531: A Novel PARP7 Inhibitor Exhibits Dual Antitumor Activity Through Immune Activation and Tumor-Intrinsic Growth Inhibition
-
- Conference presentation
- [AACR 2026] DA-4531: Dual mechanisms of PARP7 inhibition driving potent antitumor activity
-
- Conference presentation
- [AACR 2026] DA-4701: Rationally designed Allosteric EGFR Degrader SC3499 (IN-207375) Selectively Eliminates Mutant EGFR and Overcomes osimertinib resistance in Non-Small Cell Lung Cancer
-
- Conference presentation
- [AACR 2026] DA-4701: Discovery of SC3613 (IN-207387), a Mutant-Selective EGFR degrader, Exhibits Potent Anti-tumor Activity and Improved Safety Profile in EGFR TKI-Resistance in NSCLC
-
- Conference presentation
- [AACR 2025] DA-4701: Discovery of SC2073 (IN-207039), a potent and mutant selective EGFR degrader that overcomes 3rd generation EGFR inhibitors resistance in NSCLC
-
- Conference presentation
- [EORTC-NCI-AACR 2024] DA-4515, The novel potent Pan-TEAD inhibitor, SB6863, inhibits oncogenic YAP1/TAZ-TEAD signaling and exhibits robust tumor regression in preclinical mesothelioma models
-
- Conference presentation
- [AAIC 2024] DA-7503, a novel tau aggregation inhibitor, ameliorates tau pathology and reduces CSF tau in transgenic mouse models of Alzheimer’s disease and primary tauopathies
-
- Conference presentation
- [ADA 2024] DA-1726, a GLP1R/GCGR Dual Agonist, A Promising Approach in Body Composition and Lipid Management
-
- Conference presentation
- [KSBMB 2024] DA-1241, a GPR119 agonist, ameliorates fatty liver through the upregulation of TFEB mediated autophagy
-
- Conference presentation
- [EASL 2024] DA-1241, a GPR119 agonist, combined with Semaglutide synergistically improved liver fibrosis in mice with CCl4-induced liver fibrosis